AquaBounty Technologies, Inc. (NASDAQ:AQB) Short Interest Down 25.9% in January

AquaBounty Technologies, Inc. (NASDAQ:AQB) saw a significant decline in short interest in January. As of January 30th, there was short interest totaling 17,318 shares, a decline of 25.9% from the January 15th total of 23,366 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 39,938 shares, the short-interest ratio is currently 0.4 days. Based on an average daily trading volume, of 39,938 shares, the short-interest ratio is currently 0.4 days. Currently, 0.5% of the shares of the stock are short sold.

AquaBounty Technologies Trading Up 1.1%

Shares of NASDAQ:AQB opened at $0.90 on Friday. The company has a market cap of $3.49 million, a price-to-earnings ratio of -1.08 and a beta of 1.28. AquaBounty Technologies has a 12 month low of $0.50 and a 12 month high of $2.95. The company has a 50-day moving average price of $0.93 and a 200 day moving average price of $1.13.

Institutional Trading of AquaBounty Technologies

A hedge fund recently bought a new stake in AquaBounty Technologies stock. Two Sigma Investments LP bought a new stake in shares of AquaBounty Technologies, Inc. (NASDAQ:AQB) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 37,565 shares of the company’s stock, valued at approximately $84,000. Two Sigma Investments LP owned 0.97% of AquaBounty Technologies at the end of the most recent quarter. Institutional investors and hedge funds own 8.92% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AquaBounty Technologies in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, AquaBounty Technologies presently has an average rating of “Sell”.

AquaBounty Technologies Company Profile

AquaBounty Technologies, Inc is a biotechnology company focused on aquaculture innovation through the development and commercialization of genetically engineered fish. Its flagship product, AquAdvantage Salmon, is an Atlantic salmon strain enhanced with a growth hormone gene that enables faster growth and more efficient feed conversion compared with conventional farmed salmon. By integrating biotechnology into seafood production, AquaBounty aims to address global protein demand while reducing the environmental footprint associated with marine aquaculture.

Founded in 1991, AquaBounty is headquartered in Maynard, Massachusetts, and operates a state-of-the-art, land-based incubation and grow-out facility in Panama.